GIM
CYTK icon

Granahan Investment Management’s Cytokinetics CYTK Stock Holding History

Granahan Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.43M Sell
40,247
-32,217
-44% -$2.31M 0.12% 128
2026
Q1 		$4.78M Sell
72,464
-9,657
-12% -$614K 0.23% 106
2025
Q4 		$5.22M Buy
82,121
+28,571
+53% +$1.78M 0.22% 102
2025
Q3 		$2.94M Buy
+53,550
New +$2.21M 0.12% 118
2024
Q4 		– Sell
-108,957
Closed -$5.75M – 185
2024
Q3 		$5.75M Sell
108,957
-27,921
-20% -$1.56M 0.23% 116
2024
Q2 		$7.42M Buy
+136,878
New +$8.26M 0.3% 93

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Granahan Investment Management's CYTK Position: Q2 2026 in Review

Granahan Investment Management reduced its Cytokinetics (CYTK) stake by 44% in Q2 2026, selling an estimated $2.31M and leaving 40,247 shares worth $3.43M. The position accounts for 0.12% of the portfolio, ranked #128.

Granahan Investment Management first reported a position in CYTK in Q2 2024 and has held it in 6 quarters since. The position peaked at $7.42M in Q2 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Granahan Investment Management held 40,247 shares of Cytokinetics worth $3.43M as of Q2 2026.
  • Granahan Investment Management sold 32,217 Cytokinetics shares in Q2 2026, an estimated $2.31M.
  • Cytokinetics made up 0.12% of Granahan Investment Management's portfolio in Q2 2026, its #128 holding.
  • Granahan Investment Management first reported a position in Cytokinetics in Q2 2024 and has held it in 6 quarters since.
  • Granahan Investment Management's Cytokinetics position peaked at $7.42M in Q2 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Granahan Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.